These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 32259515

  • 1. Mutational heterogeneity between different regional tumour grades of clear cell renal cell carcinoma.
    Ferronika P, Kats-Ugurlu G, Haryana SM, Utoro T, Rinonce HT, Danarto R, de Lange K, Terpstra MM, Sijmons RH, Westers H, Kok K.
    Exp Mol Pathol; 2020 Aug; 115():104431. PubMed ID: 32259515
    [Abstract] [Full Text] [Related]

  • 2. Parallel evolution of tumour subclones mimics diversity between tumours.
    Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, Joshi T, Fisher R, Larkin J, Szallasi Z, Swanton C.
    J Pathol; 2013 Aug; 230(4):356-64. PubMed ID: 23716380
    [Abstract] [Full Text] [Related]

  • 3. Histology-guided proteomic analysis to investigate the molecular profiles of clear cell Renal Cell Carcinoma grades.
    Stella M, Chinello C, Cazzaniga A, Smith A, Galli M, Piga I, Grasso A, Grasso M, Del Puppo M, Varallo M, Bovo G, Magni F.
    J Proteomics; 2019 Jan 16; 191():38-47. PubMed ID: 29698802
    [Abstract] [Full Text] [Related]

  • 4. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
    Maruschke M, Reuter D, Koczan D, Hakenberg OW, Thiesen HJ.
    BJU Int; 2011 Jul 16; 108(2 Pt 2):E29-35. PubMed ID: 21435154
    [Abstract] [Full Text] [Related]

  • 5. Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis.
    Thiesen HJ, Steinbeck F, Maruschke M, Koczan D, Ziems B, Hakenberg OW.
    PLoS One; 2017 Jul 16; 12(5):e0176659. PubMed ID: 28486536
    [Abstract] [Full Text] [Related]

  • 6. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
    Serie DJ, Joseph RW, Cheville JC, Ho TH, Parasramka M, Hilton T, Thompson RH, Leibovich BC, Parker AS, Eckel-Passow JE.
    Eur Urol; 2017 Jun 16; 71(6):979-985. PubMed ID: 27899233
    [Abstract] [Full Text] [Related]

  • 7. Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma.
    Xi Y, Yuan Q, Zhang Y, Madhuranthakam AJ, Fulkerson M, Margulis V, Brugarolas J, Kapur P, Cadeddu JA, Pedrosa I.
    Eur Radiol; 2018 Jan 16; 28(1):124-132. PubMed ID: 28681074
    [Abstract] [Full Text] [Related]

  • 8. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
    Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, Hsieh JJ.
    Eur Urol; 2013 May 16; 63(5):848-54. PubMed ID: 23036577
    [Abstract] [Full Text] [Related]

  • 9. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.
    Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ.
    Cancer Med; 2014 Dec 16; 3(6):1485-92. PubMed ID: 25124064
    [Abstract] [Full Text] [Related]

  • 10. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.
    Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, Hamm D, Robins HS, Pickering L, Gore M, Nicol DL, Larkin J, Swanton C.
    J Pathol; 2013 Dec 16; 231(4):424-32. PubMed ID: 24122851
    [Abstract] [Full Text] [Related]

  • 11. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J.
    Cancer J; 2013 Dec 16; 19(4):324-32. PubMed ID: 23867514
    [Abstract] [Full Text] [Related]

  • 12. A novel highly frequent single‑nucleotide polymorphism site of cadherin 23 in clear cell renal cell carcinoma with sarcomatoid differentiation based on whole exome sequencing.
    Yu W, Wang X, Wang Y, Jiang Y, Zhang W, Shi H, Li Y.
    Oncol Rep; 2020 Aug 16; 44(2):735-746. PubMed ID: 32468012
    [Abstract] [Full Text] [Related]

  • 13. Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.
    Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S.
    Nat Commun; 2016 Jun 13; 7():ncomms11845. PubMed ID: 27291893
    [Abstract] [Full Text] [Related]

  • 14. Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma.
    Verhoest G, Patard JJ, Fergelot P, Jouan F, Zerrouki S, Dreano S, Mottier S, Rioux-Leclercq N, Denis MG.
    Urol Oncol; 2012 Jun 13; 30(4):469-75. PubMed ID: 20863722
    [Abstract] [Full Text] [Related]

  • 15. Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma.
    Köhn L, Svenson U, Ljungberg B, Roos G.
    Appl Immunohistochem Mol Morphol; 2015 Jun 13; 23(5):334-42. PubMed ID: 24992170
    [Abstract] [Full Text] [Related]

  • 16. The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.
    van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, Oromendia C, Gudas LJ, Tagawa ST, Nanus DM, Faltas BF, Beltran H, Sternberg CN, Elemento O, Sboner A, Mosquera JM, Molina AM.
    Mol Oncol; 2022 Jun 13; 16(12):2384-2395. PubMed ID: 35231161
    [Abstract] [Full Text] [Related]

  • 17. Clear cell renal cell carcinoma with prominent microvascular hyperplasia: Morphologic, immunohistochemical and molecular-genetic analysis of 7 sporadic cases.
    Alaghehbandan R, Limani R, Ali L, Rogala J, Vanecek T, Steiner P, Hajkova V, Kuthi L, Slisarenko M, Michalova K, Pivovarcikova K, Hora M, Pitra T, Michal M, Hes O.
    Ann Diagn Pathol; 2022 Feb 13; 56():151871. PubMed ID: 34847388
    [Abstract] [Full Text] [Related]

  • 18. Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes.
    Lawrie CH, Larrea E, Larrinaga G, Goicoechea I, Arestin M, Fernandez-Mercado M, Hes O, Cáceres F, Manterola L, López JI.
    J Pathol; 2014 Jan 13; 232(1):32-42. PubMed ID: 24155122
    [Abstract] [Full Text] [Related]

  • 19. Expanding the Utilization of Formalin-Fixed, Paraffin-Embedded Archives: Feasibility of miR-Seq for Disease Exploration and Biomarker Development from Biopsies with Clear Cell Renal Cell Carcinoma.
    Strauss P, Marti HP, Beisland C, Scherer A, Lysne V, Leh S, Flatberg A, Koch E, Beisvag V, Landolt L, Skogstrand T, Eikrem Ø.
    Int J Mol Sci; 2018 Mar 10; 19(3):. PubMed ID: 29534467
    [Abstract] [Full Text] [Related]

  • 20. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J.
    Nature; 2016 Nov 03; 539(7627):112-117. PubMed ID: 27595394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.